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Primary Cutaneous Marginal Zone B-Cell Lymphomas
Are Targeted by Aberrant Somatic Hypermutation
Alexander J.A. Deutsch1,4, Margareta Fru¨hwirth1, Ariane Aigelsreiter2, Lorenzo Cerroni3 and
Peter Neumeister1,4
A mechanism inducing genetic instability, termed aberrant somatic hypermutation (ASHM), has been described
in diffuse large B-cell lymphoma. To further investigate whether ASHM also occurs in primary cutaneous
marginal zone B-cell lymphoma (PCMZL), we studied the mutational profile of PAX5, RhoH/TTF, cMYC, and PIM1
in 11 PCMZLs. A total of 17 sequence variants were found in 8 of 11 lymphomas cases (72.7%), and they
displayed the molecular features typical for the ASHM. Further, two mutations, one mutation in PIM1 and one in
cMYC, led to amino-acid substitution with potential functional consequences. These data indicate that ASHM is
associated with PCMZLs. By mutating regulatory and coding sequences of the targeted genes, ASHM may
represent a major contributor to their pathogenesis.
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INTRODUCTION
The pathogenesis of most human B-cell non-Hodgkin’s
lymphomas is associated with distinct genetic lesions,
including chromosomal translocations and aberrant somatic
hypermutation (ASHM), which arise from mistakes during
class switch recombination and somatic hypermutation
occurring in the germinal center (Ku¨ppers and Dalla-Favera,
2001; Pasqualucci et al., 2001). Somatic hypermutation
occurs in germinal center B cells and is found in all germinal
center-derived B-cell tumors. This process was thought to
selectively target the rearranged V genes to generate antibody
diversity. Activation-induced cytidine deaminase (AID) is an
enzyme required for both reactions, and mistargeting of AID
to known proto-oncogenes linked to B-cell tumorigenesis in
germinal center B cells combined with a breakdown of
protective high-fidelity repair mechanism has been shown to
be a principal contributor to the pathogenesis of B-cell
non-Hodgkin’s lymphoma (Liu et al., 2008; Pasqualucci
et al., 2008). In diffuse large B-cell lymphoma somatic
hypermutation aberrantly targets the 50 sequences of several
proto-oncogenes relevant to lymphomagenesis, including
PIM1, PAX5, RhoH/TTF, and cMYC. This phenomenon,
termed ASHM, occurs in 450% of diffuse large B-cell
lymphoma, but is rare in indolent lymphomas (Pasqualucci
et al., 2001; Gaidano et al., 2003; Bodor et al., 2005; Dijkman
et al., 2006; Deutsch et al., 2007; Halldorsdottir et al., 2008).
Primary cutaneous marginal zone B-cell lymphoma
(PCMZL) is one of the most frequent types of cutaneous
B-cell lymphomas. PCMZL, an indolent lymphoma, is
considered as part of the group of extranodal marginal zone
B-cell lymphoma involving mucosal sites termed MALT
(mucosa-associated lymphoid tissue) lymphomas (Willemze
et al., 2005). PCMZL shares some histological and clinical
features with MALT lymphoma of extracutaneous origin, but
differences in biology with respect to dissemination, associa-
tion to chronic inflammation, and treatment modalities are
found between PCMZL and extracutaneous MALT lympho-
mas, suggesting that they should be considered as separate
entity (Rijlaarsdam et al., 1993; Cerroni et al., 1997a, b; Fink-
Puches et al., 2002). The present study was aimed at
investigating the role of the ASHM in PCMZL.
RESULTS
A total of 11 samples of PCMZLs were subjected to DNA
sequence analysis of PAX5, RhoH/TTF, cMYC, and PIM1
(Table 1). Of 11, 8 (72.7%) lymphoma samples showed
somatic mutation in at least one of the four analyzed genes.
Each of the four genes investigated was altered in a significant
fraction (Table 2): PAX5 was mutated in 2 of 11 (18.2%)
samples, RhoH/TTF in 3 of 11 (27.3%), cMYC in 4 of 11
(36.4%), and PIM1 in 5 of 11 (45.5%) samples. To confirm
somatic nature of these mutations, corresponding germ-line
DNA was sequenced in selected cases (corresponding to
cases 3, 10, and 11), demonstrating the tumor-specific origin.
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To rule out the occurrence of mutations in benign B cells,
Borrelia burgdorferi-infected skin lesions that are rich in
inflammatory B cells were included showing no mutations.
The detailed characterization of the mutational profile is
summarized in Table 1 and their features in Table 2. In total,
17 sequence variants were found. These mutations were
exclusively single base pair (bp) substitutions. The average
frequency of mutations, calculated taking into account only
mutated cases, ranged from 0.02102 per bp in the case of
cMYC to 0.13102 per bp in the case of RhoH/TTF; taking
all four genes together the average frequency of mutation was
0.07102 per bp (Table 2). Of the 17 mutations, 15 were
transitions and 2 were transversions corresponding to a
transition-to-transversion ratio of 7.5 (expected 0.5, if each
nucleotide is targeted at identical rate). In addition, the ratio
of GþC to AþT was shifted to a clear predominance of
GþC mutations. Four of five mutations in PIM1 and four of
five mutations in cMYC were located in the coding region,
one mutation (threonine for proline in PIM1 gene and
asparagine for aspartic acid in cMyc gene) in each gene led
to amino-acid substitution with potential functional conse-
quences (Table 1).
DISCUSSION
In PCMZL, molecular analyses show a number of distinct
cytogenetic alterations ino50% of cases (Cerroni, 2006), but
a molecular mechanism inducing genetic instability has not
yet been described. We show that 72% of PCMZL lymphoma
samples show point mutations in at least one of the four
analyzed proto-oncogenes. Although only a few PCMZL
cases were mutated at the loci of PAX5, nearly 46% of
cutaneous MALT lymphoma cases harbored mutations in the
PIM1 gene and 436% in the cMYC gene locus.
Several features of the molecular profile of mutations—
like predominance of GC over AT mutations; elevated
transition over transversion ratio, frequency of mutations
and their distribution 1–2 kb downstream of the transcription
initiation site—are similar to that detected in other lymphoma
entities, and closely resemble the one reported for IgV and
BCL6 mutations (Pasqualucci et al., 1998, 2001; Shen et al.,
1998; Storb et al., 1998; Peng et al., 1999; Gaidano et al.,
2003; Rossi et al., 2005; Deutsch et al., 2007), suggesting
ASHM to be responsible for these nucleotide alterations.
Further, mutations at these four loci have not been found in
normal germinal center B cells in diffuse large B-cell
lymphoma (Pasqualucci et al., 2001) or in inflammatory B
cells from B. burgdorferi-infected skin lesions, supporting the
hypothesis that these mutations are tumor specific and result
from an abnormal activity of the SHM mechanism. Besides
primary cutaneous follicle center lymphomas (Dijkman et al.,
2006), PCMZLs are the second cutaneous lymphoma entity
with indolent clinical course to be aberrantly targeted in
these four proto-oncogenes. However, although the muta-
tional load analyzed for all genes is higher in primary
cutaneous follicle center lymphoma (mutation frequency 0.1
vs 0.07 per 100 bp) compared to PCMZL, more PCMZL cases
(72 vs 53% ) are affected by ASHM.
Because the genes targeted by ASHM are proto-onco-
genes, introducing somatic mutations may have important
functional consequences. First, mutations clustering around
the 50-regulatory regions may deregulate gene transcription as
previously documented for cMYC (Cesarman et al., 1987).
Second, in the case of cMYC and PIM1 in which coding
sequences are also targeted causing amino-acid substitutions,
the mutations may alter structure and, subsequently, the
function of these molecules. Mutations affecting the cMYC
transactivation domain can alter the functional properties of
cMYC by interfering with its phosphorylation, protein
Table 1. Mutational analysis of PAX5, RhoH/TTF,
cMYC, and PIM1
PAX5 RhoH/TTF cMYC PIM1
Case 1 A 1414 G
Case 2
Case 3 C 4655 T A 1237 C
Case 4 T 415 C
A 449 G
Case 5
Case 6 G 882 A C 1303 T
Case 7 T 3493 C C 1306 T
Case 8
Case 9 T 936 C
Case 10 A 4608 G
C 4686 T
G 1938 A
Case 11 C 1104 T C 945 T
G 981 A
C 4693 T
Bold characters represent missense mutations.
Table 2. Distribution and feature of PAX5, RhoH/TTF, cMYC, and PIM1 mutations in PCMZL
Locus
Mutated cases/
tested (%)
Mutation frequency
per 100 bp (range)1
Single base pair
substitution G+C//A+T
Transitions over
Transversions
PAX5 2/11 (18.2) 0.097 (0.096–0.098) 2 2//0 2//0
RhoH/TTF 3/11 (27.3) 0.12 (0.10–0.13) 5 2//3 5//0
cMYC 4/11 (36.4) 0.025 (0.02–0.04) 5 3//2 4//1
PIM1 5/11 (45.5) 0.05 (0.04–0.06) 5 3//2 4//1
All genes 8/11 (72.7) 0.07 17 10//7 15//2
1Mutation frequencies were calculated on the entire region analyzed and on mutated cases only, considering two alleles per gene per case.
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stability, or repression of transactivation by the RB-related
protein p107 (Cesarman et al., 1987; Raffeld et al., 1995).
In diffuse large B-cell lymphoma, 17 of 130 (13%)
investigated genes were found involved in ASHM (Pasqualucci
et al., 2004), suggesting that a much higher number of genes
might be affected by this mechanism and that AID-mediated
mutations outside the IgV regions are a genome-wide
phenomenon (Wang et al., 2004; Liu et al., 2008). Although
the mutational profile of PAX5, RhoH/TTF, cMYC, and PIM1 of
PCMZL is similar to the mutational profile of extracutaneous
MALT lymphomas (Deutsch et al., 2007), a different targeting
of additional genes by ASHM might contribute to the different
biological behavior between PCMZL and extracutaneous
MALT lymphomas (Rijlaarsdam et al., 1993; Cerroni et al.,
1997a, b; Fink-Puches et al., 2002).
Recently, it has been demonstrated that Helicobacter
pylori infection—a risk factor for the development of gastric
cancer—triggers aberrant expression of AID in gastric
epithelium and H. pylori-mediated upregulation of AID
resulted in the accumulation of nucleotide alterations in the
TP53 tumor-suppressor gene (Matsumoto et al., 2007). As
PCR analyses show the presence of B. burgdorferi infection in
roughly 20% of cases of PCMZL (Cerroni, 2006), it is
tempting to speculate whether a similar mechanism is
responsible for some of the mutations observed in our study.
In conclusion, we demonstrate that in the majority of
PCMZLs, the proto-oncogenes PAX5, RhoH/TTF, c-MYC, and
PIM1 are targeted by ASHM. These molecular changes may
be of functional relevance in the development of PCMZLs. By
mutating regulatory and coding sequences of the targeted
genes ASHM may represent a major contributor to their
pathogenesis.
MATERIALS AND METHODS
Materials, diagnoses, and DNA extraction
DNA extraction (DNA Mini Kit; Qiagen, Valencia, CA) was
performed from formalin-fixed and paraffin-embedded macrodis-
sected tissue containing at least 90% malignant cells. A total of 11
PCMZL specimens, 3 B. burgdorferi-infected skin lesions, and 4
normal controls, including 3 nonneoplastic tissues samples of
selected lymphoma cases (corresponding to cases 3, 10, and 11),
and 1 peripheral blood mononuclear cells were included. Ethical
approval was obtained from local hospital ethics committee in
accordance with Declaration of Helsinki Principles. All lymphomas
were classified according to the European Organization for Research
and Treatment of Cancer, World Health Organization classification
for cutaneous lymphomas (Willemze et al., 2005). All specimens
were obtained from the tissue bank of the Institute of Dermatology.
Sequencing analysis of PAX5, RhoH/TTF, c-MYC, and PIM1
Mutational profile by direct DNA sequencing of PAX-5 (AF386790S2
(exon 1B):630–1450) RhoH/TTF (AF386789 (exon 1): 265–1009),
c-MYC (X00364 (exon 1 through 2): 2289–3626 and 4486–5068),
and PIM1 (AF386792 (exon 1 through 4): 780–2080) was generated
on selected regions previously described to contain 490% of
mutations (‘‘mutational hot spots’’) found in diffuse large B-cell
lymphoma (Pasqualucci et al., 2001). The initial PCR was performed
using the HotStarTaq DNA Polymerase (Qiagen, Hilden, Germany),
and all oligonucleotides were also used for sequencing (available in
Table S1). PCR products were purified and sequenced from both
sides using the BigDye terminator chemistry 3.1 (Applied Biosys-
tems, Foster City, CA). Sequences were run on an ABI3730
automated sequencer (Applied Biosystems). Sequence variants were
confirmed by two independent PCR reactions. Nucleotide changes
corresponding to previously published polymorphism were excluded
from analysis. Further, all changes occurring more than once in
separate cases were considered as polymorphic variants and were
disregarded.
Statistical analysis
Statistical analysis was performed using SPSS 15.0 (SPSS Inc.,
Chicago, IL). To calculate differences between the data set of
PCMZLs and the previously published mutational profile of
extracutaneous MALT lymphomas (Deutsch et al., 2007) Student’s
t-test was used.
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